Literature DB >> 3190102

Treatment of erythema chronicum migrans of Lyme disease.

B W Berger1.   

Abstract

Between June 1981 and July 1987 the efficacy of antibiotic treatment of 215 patients with erythema chronicum migrans of Lyme disease was evaluated in terms of the necessity for retreatment and the prevention of the late manifestations of Lyme disease. The principal antibiotics utilized to treat 161 patients through 1986 were varying doses of tetracycline, or penicillin alone or in combination with probenecid. Two of 80 patients with a minor form of the illness and 17 of 81 patients with a major form of the illness required retreatment. There were four patients who did not respond to retreatment with their original medication. A 15- to 30-day course of amoxicillin (500 mg q.i.d.) and probenecid (500 mg q.i.d.) or doxycycline (100 mg t.i.d.), and on three occasions ceftriaxone (2-4 g/day i.v.), were used to treat 54 patients in 1987. Although it is too early to judge the efficacy of treatment in these patients, increases in the incidence of Herxheimer reactions and drug eruptions were observed. Strict compliance with treatment protocols and the possibility of reactions to medications should be thoroughly discussed with patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190102     DOI: 10.1111/j.1749-6632.1988.tb31868.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  10 in total

Review 1.  Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.

Authors:  Daniel J Cameron; Lorraine B Johnson; Elizabeth L Maloney
Journal:  Expert Rev Anti Infect Ther       Date:  2014-07-30       Impact factor: 5.091

Review 2.  Childhood Lyme borreliosis in Europe.

Authors:  H I Huppertz
Journal:  Eur J Pediatr       Date:  1990-09       Impact factor: 3.183

3.  A randomized trial of ceftriaxone versus oral penicillin for the treatment of early European Lyme borreliosis.

Authors:  K Weber; V Preac-Mursic; B Wilske; R Thurmayr; U Neubert; C Scherwitz
Journal:  Infection       Date:  1990 Mar-Apr       Impact factor: 3.553

4.  Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo.

Authors:  J Alder; M Mitten; K Jarvis; P Gupta; J Clement
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

5.  Clarithromycin in treatment of early Lyme disease: a pilot study.

Authors:  R J Dattwyler; E Grunwaldt; B J Luft
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

6.  Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice.

Authors:  K D Moody; R L Adams; S W Barthold
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

7.  Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings.

Authors:  F Strle; V Preac-Mursic; J Cimperman; E Ruzic; V Maraspin; M Jereb
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

8.  Evidence of a conjugal erythromycin resistance element in the Lyme disease spirochete Borrelia burgdorferi.

Authors:  Charlene R Jackson; Julie A Boylan; Jonathan G Frye; Frank C Gherardini
Journal:  Int J Antimicrob Agents       Date:  2007-10-01       Impact factor: 5.283

Review 9.  Lyme Disease Frontiers: Reconciling Borrelia Biology and Clinical Conundrums.

Authors:  Vladimir V Bamm; Jordan T Ko; Iain L Mainprize; Victoria P Sanderson; Melanie K B Wills
Journal:  Pathogens       Date:  2019-12-16

10.  In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone.

Authors:  W A Agger; S M Callister; D A Jobe
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.